Online inquiry

IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11705MR)

This product GTTS-WQ11705MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11705MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6258MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ9328MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ2417MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ2368MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ10731MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ533MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ8896MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ2047MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW